Ibritumomab – Uses, Dosage, Side Effects, Interaction Ibritumomab tiuxetan is a monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin lymphoma via a conjugated radioactive isotope. Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chain of 445 amino acids each and two kappa light chains of 213 amino acids each. Mechanism of action The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via the production of beta particles. Binding observed on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, lymphoid follicles of the tonsil, and lymphoid nodules of other organs (e.g., large and small intestines) The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors), allowing radiation from the attached isotope (mostly beta emission) to kill it and some nearby cells. In addition, the antibody itself may trigger cell death via antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Together, these actions eliminate B cells from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.[rx] Indications Ibritumomab is used to treat relapsed or refractory, low-grade or transformed B cell non-Hodgkin’s lymphoma (NHL), a lymphoproliferative disorder, and previously untreated follicular NHL in adult patients who achieve a partial or complete response to first-line chemotherapy.[rx] The treatment should not be administered to patients with ≥25% lymphoma marrow involvement and/or impaired bone marrow reserve For the treatment of non-Hodgkin’s lymphoma Follicular Non-Hodgkin’s Lymphoma Follicular Non-Hodgkin’s Lymphoma Refractory Relapsed follicular B-cell non-Hodgkin’s lymphoma Contraindications decreased function of bone marrow increased risk of bleeding due to clotting disorder decreased blood platelets low levels of a type of white blood cell called neutrophils pregnancy a patient who is producing milk and breastfeeding a bad infection significantly decreased activity of the bone marrow anemia bleeding pregnancy Dosage Strengths: 3.2 mg/2 mL Non-Hodgkin’s Lymphoma Day 7, 8, or 9 following initial rituximab infusion: Within 4 hours of rituximab, administer Y-90 ibritumomab 0.4 mCi/kg (14.8 MBq/kg) actual body weight intravenously over 10 minutes for patients with normal platelet count (Platelet count greater than 150,000/mm3). Maximum dose: 32 mCi (1184 MBq) Y-90 ibritumomab dose regardless of actual body weight. Do not treat if platelets less than 100,000/mm3 Initiate the regimen following recovery of platelet counts to at least 150,000/mm3 at least 6 weeks, but not more than 12 weeks, following the last dose of first-line chemotherapy Dose Adjustments Platelet count between 100,000/mm3 and 149,000/mm3 (in relapsed or refractory patients): Y-90 ibritumomab 0.3 mCi/kg (11.1 MBq/kg) actual body weight intravenously over 10 minutes Administration advice: Administer Y-90 ibritumomab through a free-flowing intravenous line. Use a 0.22 micron low-protein-binding in-line filter between the syringe and the infusion port. After injection, flush the line with at least 10 mL normal saline. Side Effects The Most Common nausea vomiting stomach pain or swelling constipation heartburn loss of appetite headache anxiety dizziness difficulty falling asleep or staying asleep back, joint, or muscle pain flushing redness, tenderness, or an open wound in the area where the medication was injected redness, ulcers, or skin changes where the medicine was injected; easy bruising, unusual bleeding, purple or red spots under your skin; unusual weakness or tiredness; low red blood cells (anemia)–pale skin, weakness, cold hands and feet; or low white blood cell counts–fever, mouth sores, skin sores, sore throat, cough, trouble breathing. More common Black, tarry stools bleeding gums blood in the urine or stools cough or hoarseness coughing up blood difficulty with breathing or swallowing dizziness fever or chills headache increased menstrual flow or vaginal bleeding large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs lower back or side pain noisy breathing nosebleeds painful or difficult urination pale skin paralysis pinpoint red spots on the skin prolonged bleeding from cuts red or dark brown urine red stools shortness of breath sore throat sores, ulcers, or white spots on the lips or in the mouth swollen glands tightness in the chest troubled breathing with exertion unusual bleeding or bruising unusual tiredness or weakness wheezing Rare Bloody nose that does not stop after pinching the nose together and holding it for 5 to 10 minutes bluish lips or skin chest pain or discomfort confusion diarrhea fainting fast heartbeat hives itching lightheadedness puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue rapid, shallow breathing skin rash small red or purple spots on the skin unusual vaginal bleeding vomiting blood or material that looks like coffee grounds Agitation anxiety back pain bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, or warmth at the injection site blurred vision coma drowsiness fast, pounding, or irregular heartbeat or pulse hallucinations inability to speak irritability mood or mental changes nausea redness of the skin seizures severe headache slurred speech stiff neck temporary blindness vomiting weakness in the arm or leg on one side of the body, sudden and severe welts Blistering, peeling, or loosening of the skin cracks in the skin joint or muscle pain loss of heat from the body red skin lesions, often with a purple center red, irritated eyes red, swollen skin scaly skin skin blisters Drug Interactions Abatacept The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan. Acenocoumarol The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan. Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ibritumomab tiuxetan. Aducanumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aducanumab. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan. Alefacept The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept. Alemtuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab. Alirocumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alirocumab. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ibritumomab tiuxetan. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibritumomab tiuxetan. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Ibritumomab tiuxetan. Altretamine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine. Amivantamab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amivantamab. Amsacrine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amsacrine. Anagrelide The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Ibritumomab tiuxetan. Anifrolumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Ibritumomab tiuxetan. Ansuvimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ansuvimab. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Ibritumomab tiuxetan. Antilymphocyte The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ibritumomab tiuxetan. Antithrombin III The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan. Antithymocyte The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit). Apixaban The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan. Apremilast The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apremilast. Ardeparin The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Ibritumomab tiuxetan. Arsenic trioxide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Arsenic trioxide. Asfotase alfa The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asfotase alfa. ACOVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Atezolizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atezolizumab. Atoltivimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atoltivimab. Avelumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Avelumab. Azacitidine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azathioprine. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ibritumomab tiuxetan. Bacillusantigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Ibritumomab tiuxetan. Bacillus antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ibritumomab tiuxetan. Bamlanivimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bamlanivimab. Baricitinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Ibritumomab tiuxetan. Beclomethasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Beclomethasone dipropionate. Belantamab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Ibritumomab tiuxetan. Bendamustine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibritumomab tiuxetan. Benralizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Benralizumab. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ibritumomab tiuxetan. Besilesomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Besilesomab. Betamethasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Betamethasone. Betrixaban The risk or severity of adverse effects can be increased when Betrixaban is combined with Ibritumomab tiuxetan. Bevacizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab. Bexarotene The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene. Bezlotoxumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bezlotoxumab. Bimekizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimekizumab. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Ibritumomab tiuxetan. Bleomycin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin. Blinatumomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blinatumomab. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. Bortezomib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib. Bosutinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib. Brentuximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brentuximab vedotin. Brodalumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brodalumab. Brolucizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brolucizumab. Budesonide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Budesonide. Burosumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Burosumab. Busulfan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan. Cabazitaxel The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cabazitaxel. Canakinumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Canakinumab. Cangrelor The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan. Capecitabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capecitabine. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan. Capromab pendetide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide. Carbamazepine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine. Casirivimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Catumaxomab. Cemiplimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab. Certolizumab pegol The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Certolizumab pegol. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan. Chlorambucil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chlorambucil. Chloramphenicol The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chloramphenicol. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibritumomab tiuxetan. Ciclesonide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide. Cilgavimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cilgavimab. Cilostazol The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan. Cisplatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin. You Might Also Read Pioglitazone; Uses, Contra indications, Dosage, Side Effects, Drug Interactions Cladribine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cladribine. Clobetasol The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine. Clopidogrel The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. Clozapine The risk or severity of neutropenia can be increased when Ibritumomab tiuxetan is combined with Clozapine. Coestrogens Conjugated estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan. Corticotropin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibritumomab tiuxetan. Cyclophosphamide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cyclophosphamide. Cyclosporine Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibritumomab tiuxetan. Cytarabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine. Dabigatran The risk or severity of adverse effects can be increased when Dabigatran is combined with Ibritumomab tiuxetan. Dabigatran The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan. Dacarbazine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine. Dactinomycin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Ibritumomab tiuxetan. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Ibritumomab tiuxetan. Daratumumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daratumumab. Dasatinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Decitabine. Defibrotide The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan. Deflazacort The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Ibritumomab tiuxetan. Desoximetasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Desoximetasone. Deucravacitinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone. Dexrazoxane The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Ibritumomab tiuxetan. Dicoumarol The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan. Dienestrol Dienestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. Difluocortolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Difluocortolone. Digoxin The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan. Dimethyl fumarate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dinutuximab. Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan. Diroximel f The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Diroximel fumarate. Docetaxel The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Docetaxel. Dostarlimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dostarlimab. Doxorubicin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxorubicin. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan. Dulaglutide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dulaglutide. Dupilumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab. Durvalumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Durvalumab. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ibritumomab tiuxetan. Eculizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Ibritumomab tiuxetan. Edoxaban The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan. Efalizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab. Eflapegrastim The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eflapegrastim. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eftrenonacog alfa. Elotuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Elotuzumab. Emapalumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab. Emicizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emicizumab. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Ibritumomab tiuxetan. Epirubicin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin. Epoprostenol The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan. Eptifibatide The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan. Eptinezumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab. Erenumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Erenumab. Eribulin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin. Es estrogens Esterified estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan. Estetrol Estetrol may increase the thrombogenic activities of Ibritumomab tiuxetan. Estradiol Estradiol may increase the thrombogenic activities of Ibritumomab tiuxetan. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Ibritumomab tiuxetan. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Ibritumomab tiuxetan. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Ibritumomab tiuxetan. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Ibritumomab tiuxetan. Estramustine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Estramustine. Estriol Estriol may increase the thrombogenic activities of Ibritumomab tiuxetan. Estrone Estrone may increase the thrombogenic activities of Ibritumomab tiuxetan. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Ibritumomab tiuxetan. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Ibritumomab tiuxetan. Etoposide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide. Everolimus The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Everolimus. Evolocumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evolocumab. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Ibritumomab tiuxetan. Fanolesomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fanolesomab. Filgotinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Filgotinib. Fingolimod Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod. Floxuridine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Floxuridine. Flucytosine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludrocortisone. Fluindione The risk or severity of adverse effects can be increased when Fluindione is combined with Ibritumomab tiuxetan. Flunisolide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flunisolide. Fluocinolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide. Fluocinonide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorometholone. Fluorouracil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ibritumomab tiuxetan. Fluprednisolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednisolone. Fluticasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone. Fluticasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone furoate. Fluticasone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone propionate. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Ibritumomab tiuxetan. Fremanezumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fremanezumab. Galcanezumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab. Gallium nitrate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gallium nitrate. Gemcitabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gemcitabine. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan. Glatiramer The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glatiramer. Golimumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Golimumab. Guselkumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab. You Might Also Read Psyllium Husk Capsules - Uses, Dosage, Side Effects Ipilimumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab. Irinotecan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan. Isatuximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Isatuximab. Ixabepilone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixekizumab. JaCOVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Jap encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. Lanadelumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lanadelumab. Leflunomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lenalidomide. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan. Linezolid The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Linezolid. Lipegfilgrastim Ibritumomab tiuxetan may increase the myelosuppressive activities of Lipegfilgrastim. Lomustine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lomustine. Loncastuximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Loncastuximab tesirine. Lopinavir The serum concentration of Ibritumomab tiuxetan can be increased when it is combined with Lopinavir. Maftivimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Maftivimab. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Ibritumomab tiuxetan. Margetuximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Margetuximab. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Ibritumomab tiuxetan. Mechlorethamine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine. Melphalan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Mepolizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine. Mestranol Mestranol may increase the thrombogenic activities of Ibritumomab tiuxetan. Methimazole The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methotrexate. Methylprednisolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone. Mirvetuximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mirvetuximab Soravtansine. Mitomycin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin. Mitoxantrone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitoxantrone. MCOVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ibritumomab tiuxetan. Mogamulizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mogamulizumab. Mometasone furoate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone furoate. Monomethyl The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Monomethyl fumarate. Mosunetuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mosunetuzumab. Mumps virus strain The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Ibritumomab tiuxetan. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan. Mycophenolate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolic acid. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Ibritumomab tiuxetan. Natalizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab. Necitumumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Necitumumab. Nelarabine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nelarabine. Nilotinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nilotinib. Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan. Nivolumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nivolumab. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Ibritumomab tiuxetan. Obiltoxaximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obiltoxaximab. Obinutuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Ibritumomab tiuxetan. Odesivimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ofatumumab. Olaparib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib. Olaratumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaratumab. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibritumomab tiuxetan. Oxaliplatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin. Ozanimod The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paclitaxel. Palbociclib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan. Palivizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab. Panitumumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panitumumab. Panobinostat The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panobinostat. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Ibritumomab tiuxetan. Pazopanib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan. Pegcetacoplan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pegcetacoplan. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan. Peginterferon The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peginterferon beta-1a. Pembrolizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pembrolizumab. Pemetrexed The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pemetrexed. Penicillamine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Penicillamine. Pentosan The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Ibritumomab tiuxetan. Pentostatin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin. Pentoxifylline The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Pertuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pertuzumab. Phenindione The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan. Phenprocoumon The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan. Phenylalanine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan. Pirfenidone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirfenidone. Polatuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Polatuzumab vedotin. Polyestradiol Polyestradiol phosphate may increase the thrombogenic activities of Ibritumomab tiuxetan. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibritumomab tiuxetan. Pomalidomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponesimod. Pralatrexate The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate. Prasugrel The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan. Prednisolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisone. Procarbazine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Procarbazine. Propylthiouracil The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Ibritumomab tiuxetan. Protein S The risk or severity of bleeding can be increased when Protein S human is combined with Ibritumomab tiuxetan. Quinestrol Quinestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ibritumomab tiuxetan. Rabies antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan. Rabies antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ibritumomab tiuxetan. Raltitrexed The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed. Ramucirumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ramucirumab. Ranibizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ranibizumab. Ravulizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ravulizumab. Raxibacumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raxibacumab. Reslizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Reslizumab. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Ibritumomab tiuxetan. Rilonacept The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilonacept. Risankizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Risankizumab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan. Rivaroxaban The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan. Roflumilast Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan. Romosozumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Romosozumab. Ropeginter The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ropeginterferon alfa-2b. Rotavirus vacci The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Rubella virus The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibritumomab tiuxetan. Ruxolitinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib. Sacituzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sacituzumab govitecan. Sarilumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Satralizumab. Secukinumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Secukinumab. Siltuximab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siltuximab. Siponimod The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan. Sirolimus The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirolimus. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Ibritumomab tiuxetan. Sodium citrate The risk or severity of adverse effects can be increased when Sodium citrate is combined with Ibritumomab tiuxetan. Sorafenib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sorafenib. Sotrovimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Spesolimab. You Might Also Read Sitagliptin; Uses, Dosage, Side Effects, Drug Interactions Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan. Streptozocin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin. Sulesomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulesomab. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ibritumomab tiuxetan. Sulfasalazine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine. Sulfinpyrazone The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ibritumomab tiuxetan. Sulodexide The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan. Sunitinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sunitinib. Sutimlimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sutimlimab. SEstrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ibritumomab tiuxetan. S Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Ibritumomab tiuxetan. Tafasitamab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Ibritumomab tiuxetan is combined with Tedizolid phosphate. Temozolomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temozolomide. Temsirolimus The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Ibritumomab tiuxetan. Teniposide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide. Teplizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teplizumab. Teprotumumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teprotumumab. Teriflunomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teriflunomide. Tetanus immune The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetanus immune globulin, human. Tezepelumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tezepelumab. Thalidomide The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thalidomide. Thiotepa The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thiotepa. Tibolone Tibolone may increase the thrombogenic activities of Ibritumomab tiuxetan. Ticagrelor The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan. Tick encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. Ticlopidine The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan. Tildrakizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tildrakizumab. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Ibritumomab tiuxetan. Tioguanine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine. Tirofiban The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan. Tisotumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tisotumab vedotin. Tixagevimab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixagevimab. Tixocortol The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixocortol. Tocilizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tocilizumab. Tofacitinib Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib. Topotecan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan. Tositumomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab. Trabectedin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trabectedin. Tralokinumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tralokinumab. Trastuzumab Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan. Trastuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab deruxtecan. Trastuzumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab emtansine. Tremelimumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tremelimumab. Tretinoin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tretinoin. Triamcinolone The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triamcinolone. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibritumomab tiuxetan. Trifluridine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trifluridine. Triflusal The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan. Trilostane The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trilostane. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ibritumomab tiuxetan. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ibritumomab tiuxetan. Upadacitinib The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Ibritumomab tiuxetan. Ustekinumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ustekinumab. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ibritumomab tiuxetan. Varicella The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Ibritumomab tiuxetan. Vedolizumab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vedolizumab. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ibritumomab tiuxetan. Vilanterol The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilanterol. Vinblastine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine. Vincristine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine. Vindesine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine. Vinorelbine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinorelbine. Voclosporin The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Voclosporin. Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan. Vorinostat The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vorinostat. Warfarin The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan. Ximelagatran The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan. Yel fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Ibritumomab tiuxetan. Zidovudine The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine. Pregnancy and Lactation US FDA pregnancy category: Unassigned Pregnancy This drug may cause fetal harm when administered to a pregnant woman. Potential fetal risk should be considered and informed if pregnancy occurs while receiving treatment with this drug. Encourage male and female patients to use adequate methods of contraception during and for a minimum of 12 months following treatment. Pregnancy testing in females should be conducted prior to treatment. Lactation Use should be avoided during treatment, and for 6 months after the last dose. According to some authorities, the use during lactation is contraindicated. Excreted into human milk: Unknown Excreted into animal milk: Unknown There is no information regarding this drug on its presence in human milk, its effects on a breastfed infant, or its effects on milk production. How should this medicine be used? Ibritumomab injection comes as a liquid to be injected into a vein over 10 minutes by a doctor who has been trained to treat patients with radioactive medication. It is given as part of a specific cancer treatment regimen. On the first day of the treatment regimen, a dose of rituximab is given and the first dose of ibritumomab injection is given no more than 4 hours afterward. Imaging scans to see how ibritumomab injection has spread through the body are performed 48 to 72 hours after the dose of ibritumomab injection is given. Additional scans may be performed if needed during the next several days. If the results of the scan(s) show that the ibritumomab injection has spread through the body as expected, the second dose of rituximab and a second dose of ibritumomab injection will be given 7 to 9 days after the first doses were given. What special precautions should I follow? Before receiving an ibritumomab injection, tell your doctor and pharmacist if you are allergic to ibritumomab, any of the medications mentioned in the IMPORTANT WARNING section, any other medications, or any of the ingredients in ibritumomab injection. Ask your doctor or pharmacist for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had any medical condition. tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are receiving ibritumomab. If you are female, you will need to take a pregnancy test before starting treatment and use birth control to prevent pregnancy during your treatment and for 12 months after your final dose. If you are a male with a female partner, use birth control to prevent pregnancy during your treatment and for 12 months after your final dose. If you or your partner become pregnant while receiving ibritumomab injection, call your doctor immediately. Ibritumomab injection may harm the fetus. tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while receiving ibritumomab and for 6 months after your final dose. you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving ibritumomab. if you are having surgery, including dental surgery, tell the doctor or dentist that you have received ibritumomab injection. do not have any vaccinations during treatment and for 12 months after your final dose without first talking to your doctor. you should know that the radioactivity in the second dose of ibritumomab injection may be present in your body fluids for up to a week after you receive the dose. To prevent the radioactivity from spreading to people who are in close contact with you, you should be sure to wash your hands thoroughly after using the bathroom, use a condom every time you have sexual intercourse, and avoid deep kissing. Follow these precautions during your treatment and for 7 days after you receive your second dose of ibritumomab injection. you should know that ibritumomab injection contains albumin (a product that is made from live donor blood). Although there is an extremely small chance that viruses may be spread through the blood, no cases of viral diseases from this product have been reported. you should know that if you receive ibritumomab injection, your body may develop antibodies (substances in the blood that help the immune system recognize and attack foreign substances) to murine proteins. If you develop these antibodies, you may have an allergic reaction when you take medications made from murine proteins, or these medications might not work well for you.After your treatment with ibritumomab injection, be sure to tell all of your doctors that you have been treated with ibritumomab injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125019s0156.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125019s210s213lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125019_0000_ZevalinTOC.cfm/ https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/ibriide021902lb.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Ibritumomab https://pubchem.ncbi.nlm.nih.gov/compound/Ibritumomab https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan https://go.drugbank.com/drugs/DB00078 https://www.drugs.com/mtm/ibritumomab.html https://medlineplus.gov/druginfo/meds/a609012.html https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan https://www.mayoclinic.org/drugs-supplements/ibritumomab-intravenous-route/side-effects/drg-20064224 https://www.webmd.com/drugs/2/drug-64392/kit-for-yttrium-90-ibritumomab-intravenous/details/list-contraindications References